Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma.
epigenetic drug
glioblastoma
histone deacetylase
magnetic resonance spectroscopy
radiation sensitizer
Journal
Tomography (Ann Arbor, Mich.)
ISSN: 2379-139X
Titre abrégé: Tomography
Pays: Switzerland
ID NLM: 101671170
Informations de publication
Date de publication:
03 03 2022
03 03 2022
Historique:
received:
09
01
2022
revised:
24
02
2022
accepted:
28
02
2022
entrez:
22
3
2022
pubmed:
23
3
2022
medline:
25
3
2022
Statut:
epublish
Résumé
Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood-brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical trial was to assess the efficacy of combining belinostat with standard-of-care therapy. Thirteen patients were enrolled in each of control and belinostat cohorts. The belinostat cohort was given a belinostat regimen (500-750 mg/m
Identifiants
pubmed: 35314634
pii: tomography8020057
doi: 10.3390/tomography8020057
pmc: PMC8938806
doi:
Substances chimiques
Hydroxamic Acids
0
Sulfonamides
0
belinostat
F4H96P17NZ
Types de publication
Controlled Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
688-700Subventions
Organisme : NCI NIH HHS
ID : F31 CA247564
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008169
Pays : United States
Organisme : NIBIB NIH HHS
ID : U01 EB028145
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA172027
Pays : United States
Références
Curr Probl Diagn Radiol. 2021 May-Jun;50(3):356-361
pubmed: 32081518
Neuro Oncol. 2017 May 1;19(5):669-677
pubmed: 28453749
Oncologist. 2007 Oct;12(10):1247-52
pubmed: 17962618
NMR Biomed. 2006 Jun;19(4):492-503
pubmed: 16763967
Pract Radiat Oncol. 2016 Sep-Oct;6(5):298-305
pubmed: 26952812
J Clin Oncol. 2017 Jan 20;35(3):361-369
pubmed: 27893327
Radiol Oncol. 2018 Jun 06;52(2):121-128
pubmed: 30018514
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Nat Med. 2011 Mar;17(3):291-3
pubmed: 21383741
Magn Reson Med. 2015 Nov;74(5):1209-20
pubmed: 25354190
Tomography. 2019 Mar;5(1):184-191
pubmed: 30854456
Oxf Med Case Reports. 2020 Mar 30;2020(3):omaa006
pubmed: 32257248
Neuro Oncol. 2016 Aug;18(8):1180-9
pubmed: 26984746
PLoS One. 2013 Jul 26;8(7):e69964
pubmed: 23922875
Clin Epigenetics. 2019 Jan 17;11(1):11
pubmed: 30654849
J Am Coll Radiol. 2018 May;15(5):767-771
pubmed: 29503151
Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):29-38
pubmed: 24380043
Magn Reson Med. 2009 Mar;61(3):548-59
pubmed: 19111009
Acad Radiol. 2019 Jul;26(7):974-980
pubmed: 30661977
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):130-6
pubmed: 20399036
JAMA. 2015 Dec 15;314(23):2535-43
pubmed: 26670971
Clin Cancer Res. 2015 Jun 15;21(12):2666-70
pubmed: 25802282
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Tomography. 2019 Mar;5(1):53-60
pubmed: 30854442